Loading...
XHKG
2289
Market cap107mUSD
May 02, Last price  
7.75HKD
Name

Charmacy Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
15.17
P/S
0.18
EPS
0.48
Div Yield, %
4.26%
Shrs. gr., 5y
—
Rev. gr., 5y
2.27%
Revenues
4.40b
+5.47%
2,401,231,0003,014,059,0003,397,133,0003,669,781,0914,095,835,4493,935,245,9763,492,782,9113,991,710,5233,793,617,7194,175,279,0394,403,633,478
Net income
51m
-43.25%
22,219,00036,445,00026,359,00059,348,00044,759,91145,432,94940,153,35540,555,96523,153,06090,471,95651,344,725
CFO
0k
-100.00%
45,104,000-14,826,000193,670,000-101,551,472-32,960,13849,151,3964,018,929131,076,849-19,543,39344,050,3010
Dividend
May 22, 20240.32977 HKD/sh
Earnings
May 20, 2025

Profile

Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, healthcare products, and related consulting services to downstream distributors and terminal chemists. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online and make inquiries and payments. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.
URL
https://www.chmyy.com/
IPO date
Dec 14, 2015
Employees
817
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,403,633
5.47%
4,175,279
10.06%
Cost of revenue
4,281,693
4,069,237
Unusual Expense (Income)
NOPBT
121,940
106,042
NOPBT Margin
2.77%
2.54%
Operating Taxes
16,075
31,673
Tax Rate
13.18%
29.87%
NOPAT
105,865
74,369
Net income
51,345
-43.25%
90,472
290.76%
Dividends
(75,500)
Dividend yield
5.39%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,531,069
1,390,027
Long-term debt
67,368
31,510
Deferred revenue
Other long-term liabilities
601
1
Net debt
953,680
542,993
Cash flow
Cash from operating activities
44,050
CAPEX
(40,849)
(8,589)
Cash from investing activities
39,337
71,762
Cash from financing activities
101,262
(191,212)
FCF
28,986
(14,161)
Balance
Cash
644,756
503,807
Long term investments
374,737
Excess cash
424,575
669,780
Stockholders' equity
319,805
316,480
Invested Capital
1,840,062
1,589,628
ROIC
6.17%
4.33%
ROCE
5.65%
5.56%
EV
Common stock shares outstanding
108,003
107,994
Price
12.96
90.59%
6.80
21.86%
Market cap
1,399,722
90.60%
734,361
21.87%
EV
2,353,402
1,277,354
EBITDA
148,410
134,879
EV/EBITDA
15.86
9.47
Interest
40,790
35,073
Interest/NOPBT
33.45%
33.07%